samedan logo

 
 
spacer
home > ebr > winter 2003 > will demand exceed supply for biopharmaceutical manufacturing?
PUBLICATIONS
European Biopharmaceutical Review

Will Demand Exceed Supply for Biopharmaceutical Manufacturing?

Manufacturing capacities have increasingly become cause for much speculation; many biopharmaceutical market participants consider this to be a crucial issue which will make or break the industry's progression. Once a new drug is discovered and clinical trials are conducted and approved by the drug approval authorities, the actual task of manufacture for commercial application begins. Construction of manufacturing facilities is not an easy task and requires anywhere between three to five years with a typical investment of around US$500 million. In the current economic situation, where raising capital is a difficult undertaking, building biopharmaceutical manufacturing reactors is not easy.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Raju Adhikari, Mbiochem, Dphil, Research Analyst at Frost and Sullivan, Europe

Raju Adhikari, Mbiochem, DPhil is a Research Analyst at Frost and Sullivan, Europe. Since joining Frost and Sullivan, Raju has been involved in the research, analysis and production of market studies in the biotechnology field. His experience in the biotechnology sector comes from three years spent working at Everest Biotechnology Ltd, an emerging antibody company. As Chief Scientific Officer, his role involved Product Management, Business Development, Quality Control and Marketing/PR. Raju graduated with a First Class Masters degree from the University of Oxford. He received his doctorate, also from the University of Oxford, in the field of Immunology and has published several papers in scientific journals.

spacer
Raju Adhikari
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Turkish Cargo expands the ‘Pharma Corridor’ in its wide flight network.

Turkish Cargo, the fastest growing global air cargo brand thanks to its wide flight network, keeps bringing health to the world by carrying pharmaceuticals between destinations certified by the global aviation authorities. The successful brand has created a pharma corridor between over 400 stations by carrying pharmaceuticals in important and certified destinations such as Mumbai, Brussels, Istanbul, Singapore, Dubai, Basel, London, and Amsterdam.
More info >>

White Papers

Speciality Logistics Outlook 2015

World Courier

To date, there are more than 178,000 registered clinical trials taking place across the globe, and global pharma’s volume has more than doubled over the last decade. With emerging markets showing explosive predictive growth through 2016, shippers and trial sponsors can expect continued regulatory and overall logistics complexities that foster demand for local, inmarket resources across the globe.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement